You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

AP26113

Showing 1 - 8 of 8
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Malignant Tumor, ALK Fusion Protein Expression, ALK Gene Amplification Trial in Columbus (Brigatinib, Laboratory

Withdrawn
  • Advanced Malignant Neoplasm
  • +10 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 15, 2022

Lymphoma, Large-Cell, Anaplastic, NSCLC Trial (Brigatinib)

Completed
Has Results
  • Lymphoma, Large-Cell, Anaplastic
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Jul 26, 2021

Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell

Recruiting
  • Locally Advanced Lung Non-Small Cell Carcinoma
  • +9 more
  • Duarte, California
  • +4 more
Aug 17, 2022

NSCLC Trial (Brigatinib)

Completed
Has Results
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Feb 18, 2021

NSCLC Trial in United States (brigatinib)

Terminated
Has Results
  • Non-Small Cell Lung Cancer
  • Denver, Colorado
  • +3 more
Jan 10, 2023

ALK-positive Advanced NSCLC Trial in Worldwide (Brigatinib)

Active, not recruiting
Has Results
  • ALK-positive Advanced NSCLC
  • Orange, California
  • +79 more
Nov 15, 2022

NSCLC, Lung Cancer, Advanced Malignancies Trial in Worldwide (Brigatinib, Crizotinib)

Completed
Has Results
  • Non-small Cell Lung Cancer
  • +3 more
  • Sedona, Arizona
  • +90 more
Jul 27, 2021

NSCLC, Lung Cancer, Advanced Malignancies Trial in La Jolla, Orange, Detroit (Brigatinib)

No longer available
  • Non-small Cell Lung Cancer
  • +3 more
  • La Jolla, California
  • +2 more
Feb 5, 2018